Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

DGAP-Adhoc: RHÖN-KLINIKUM AG einigt sich mit dem Land Hessen über Absichtserklärung zu Investitionsfördermitteln: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23735/Rhoen-klinikum.svg.png
DGAP-Adhoc: RHÖN-KLINIKUM AG einigt sich mit dem Land Hessen über Absichtserklärung zu Investitionsfördermitteln
DGAP-Adhoc: RHÖN-KLINIKUM AG einigt sich mit dem Land Hessen über Absichtserklärung zu Investitionsfördermitteln
Premier Inc.’s Contigo Health Expands Provider-Sponsored Health Plan Offerings Through New Partnership With OhioHealthy: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier Inc.’s Contigo Health Expands Provider-Sponsored Health Plan Offerings Through New Partnership With OhioHealthy


Contigo Health LLC, a subsidiary of Premier Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced a new partnership with OhioHealthy Plans, LLC

LivaNova to Announce Fourth-Quarter and Full-Year 2021 Results: https://mms.businesswire.com/media/20191101005329/en/555341/5/LN-Logo-Main-PANTONE.jpg
LivaNova to Announce Fourth-Quarter and Full-Year 2021 Results


LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its fourth-quarter and full-year 2021 results on Wednesday, February

ICON Issues Financial Guidance for Full Year 2022: https://mms.businesswire.com/media/20191114005374/en/602293/5/ICON_Positive_logo_PNG_%28nostrap%29.jpg
ICON Issues Financial Guidance for Full Year 2022


ICON plc, (NASDAQ: ICLR), a world-leading clinical research organisation powered by healthcare intelligence, today announced its financial guidance for the year ended December 31, 2022. For the

Xencor Highlights 2022 Corporate Priorities and Portfolio Milestones: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor Highlights 2022 Corporate Priorities and Portfolio Milestones


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced

Charles River Laboratories Announces Chief Financial Officer Retirement and Transition Plan: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River Laboratories Announces Chief Financial Officer Retirement and Transition Plan


Charles River Laboratories International, Inc. (NYSE: CRL) today announced a retirement and transition plan for its Chief Financial Officer.



David R. Smith, Corporate Executive Vice President and

DGAP-News: Evotec erweitert Neurologie-Kooperation mit Bristol Myers Squibb um neuen Ansatz zum gezielten Proteinabbau : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
DGAP-News: Evotec erweitert Neurologie-Kooperation mit Bristol Myers Squibb um neuen Ansatz zum gezielten Proteinabbau
DGAP-News: Evotec erweitert Neurologie-Kooperation mit Bristol Myers Squibb um neuen Ansatz zum gezielten Proteinabbau
DGAP-News: Evotec expands neuroscience collaboration with Bristol Myers Squibb to include new targeted protein degradation approach: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
DGAP-News: Evotec expands neuroscience collaboration with Bristol Myers Squibb to include new targeted protein degradation approach
DGAP-News: Evotec expands neuroscience collaboration with Bristol Myers Squibb to include new targeted protein degradation approach
QIAGEN expands QIAstat-Dx syndromic testing menu and announces launch plans for new QIAstat-Dx Rise higher-throughput version
QIAGEN expands QIAstat-Dx syndromic testing menu and announces launch plans for new QIAstat-Dx Rise higher-throughput version


QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced important enhancements in the commercialization of its QIAstat-Dx syndromic testing solution – which enables laboratories and

QIAGEN erweitert QIAstat-Dx-Menü um weitere syndromische Tests und kündigt Pläne zur Einführung der neuen Version QIAstat-Dx Rise mit höherem Durchsatz an
QIAGEN erweitert QIAstat-Dx-Menü um weitere syndromische Tests und kündigt Pläne zur Einführung der neuen Version QIAstat-Dx Rise mit höherem Durchsatz an


QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute bedeutende Fortschritte bei der Kommerzialisierung seiner syndromischen Testlösung QIAstat-Dx bekannt, mit der Labore und

AMN Healthcare Announces Preliminary Fourth Quarter 2021 Revenue; To Present at J.P. Morgan Healthcare Conference: https://mms.businesswire.com/media/20201201005032/en/841855/5/AMN-Logo.jpg
AMN Healthcare Announces Preliminary Fourth Quarter 2021 Revenue; To Present at J.P. Morgan Healthcare Conference


AMN Healthcare Services (NYSE: AMN) is providing preliminary unaudited consolidated revenue results for the fourth quarter of 2021 to facilitate the Company’s participation in the 40th Annual J.P

Novocure Announces Preliminary Full Year and Fourth Quarter 2021 Net Revenues and Provides Company Update: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Announces Preliminary Full Year and Fourth Quarter 2021 Net Revenues and Provides Company Update


Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial results and operational updates for the quarter and full year ended December 31, 2021.* Novocure is a global oncology company

DGAP-News: MorphoSys präsentiert auf der 40. jährlichen J.P. Morgan Healthcare Conference: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys präsentiert auf der 40. jährlichen J.P. Morgan Healthcare Conference
DGAP-News: MorphoSys präsentiert auf der 40. jährlichen J.P. Morgan Healthcare Conference
DGAP-News: MorphoSys To Present At the 40th Annual J.P. Morgan Healthcare Conference: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys To Present At the 40th Annual J.P. Morgan Healthcare Conference
DGAP-News: MorphoSys To Present At the 40th Annual J.P. Morgan Healthcare Conference
QIAGEN stärkt das wachsende Anwendungsportfolio seiner digitalen PCR-Plattform QIAcuity mit neuen Kooperationen
QIAGEN stärkt das wachsende Anwendungsportfolio seiner digitalen PCR-Plattform QIAcuity mit neuen Kooperationen


QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute Informationen zu zwei Neuzugängen im wachsenden Anwendungsportfolio von QIAcuity, seiner Plattform zur Durchführung

QIAGEN Strengthens Growing Portfolio of Applications for Its Digital PCR Platform QIAcuity With New Collaborations
QIAGEN Strengthens Growing Portfolio of Applications for Its Digital PCR Platform QIAcuity With New Collaborations


QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new additions to the growing number of applications for QIAcuity, its ultrasensitive digital PCR (dPCR) platform that has set

DGAP-News: MorphoSys Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance
DGAP-News: MorphoSys Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance
DGAP-News: MorphoSys gibt vorläufigen Monjuvi-Umsatz für 2021 bekannt und veröffentlicht Finanzprognose für 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys gibt vorläufigen Monjuvi-Umsatz für 2021 bekannt und veröffentlicht Finanzprognose für 2022
DGAP-News: MorphoSys gibt vorläufigen Monjuvi-Umsatz für 2021 bekannt und veröffentlicht Finanzprognose für 2022
DGAP-Adhoc: MorphoSys AG gibt vorläufigen Monjuvi-Umsatz für 2021 bekannt und veröffentlicht Finanzprognose für 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-Adhoc: MorphoSys AG gibt vorläufigen Monjuvi-Umsatz für 2021 bekannt und veröffentlicht Finanzprognose für 2022
DGAP-Adhoc: MorphoSys AG gibt vorläufigen Monjuvi-Umsatz für 2021 bekannt und veröffentlicht Finanzprognose für 2022
DGAP-Adhoc: MorphoSys AG Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-Adhoc: MorphoSys AG Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance
DGAP-Adhoc: MorphoSys AG Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance
Xencor to Present at the H.C. Wainwright Bioconnect Virtual Conference: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor to Present at the H.C. Wainwright Bioconnect Virtual Conference


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced

QIAGEN Expands QuantiFERON Portfolio in the Fight Against TB
QIAGEN Expands QuantiFERON Portfolio in the Fight Against TB


QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced important expansion initiatives for its QuantiFERON franchise, building on its status as the gold standard for detection of

QIAGEN erweitert sein QuantiFERON-Portfolio im Kampf gegen TB
QIAGEN erweitert sein QuantiFERON-Portfolio im Kampf gegen TB


QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute Details zur Erweiterung seines QuantiFERON-Portfolios bekannt. Basierend auf dem Status von QuantiFERON als Goldstandard zur

Acadia Healthcare to Present at the 40th Annual J.P. Morgan Healthcare Conference: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare to Present at the 40th Annual J.P. Morgan Healthcare Conference


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will present virtually at the 40th Annual J.P. Morgan Healthcare Conference, which takes place January 10 – January

Charles River Laboratories to Present at J.P. Morgan Healthcare Conference: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference


Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will virtually present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11th, at 10:30